Drug Type Bispecific antibody |
Synonyms- |
Target |
Mechanism CD3 inhibitors(T cell surface glycoprotein CD3 inhibitors), GD2 inhibitors(Disialoganglioside GD2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Melanoma | Preclinical | DE | 03 Aug 2024 | |
Neuroblastoma | Preclinical | DE | 03 Aug 2024 | |
Sarcoma | Preclinical | DE | 03 Aug 2024 |